Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the populationbased Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks.
Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the populationbased Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019; 85:155-160 T here is a great deal of interest in biomarker-based staging of preclinical Alzheimer disease (AD), in part due to ongoing development of therapies for early intervention. 1, 2 In the National Institute on Aging-Alzheimer's Association committees in 2011, 2 classes of AD biomarkers were identified: measures of amyloid (A) by cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET) and measures of neuronal injury (N) by CSF, fluorodeoxyglucose (FDG) PET, or magnetic resonance imaging (MRI). [3] [4] [5] When cognitively unimpaired (CU) individuals are categorized based on having normal (−) or abnormal (+) levels of A and N, the A+N+ group consistently has an elevated risk of progression to subsequent cognitive impairment. 6, 7 Whether A−N+, also termed suspected non-Alzheimer pathophysiology (SNAP), 8 is a risk factor for cognitive impairment is an important open question. Furthermore, little is known about the implications of these biomarkers in terms of absolute risk of cognitive impairment for the elderly patient in clinical practice. Data most relevant to clinical practice should come from community-based studies, rather than highly selected referral samples, and should provide predictive information at the individual patient level. To address both of these gaps in current knowledge, we evaluated the role of imaging-based biomarkers of A and N in predicting progression from CU to mild cognitive impairment (MCI) or dementia for individual patients in a population-based study of aging and cognition. 9 
Subjects and Methods

Study Design and Participants
All participants in this study were enrolled in the Mayo Clinic Study of Aging (MCSA), a longitudinal, population-based study of residents of Olmsted County, Minnesota, 9 and participated in brain imaging. MCSA participants were evaluated clinically approximately every 15 months. Each evaluation included separate assessments by a study coordinator, a physician, and a psychometrist. 9 The final clinical diagnosis is determined by consensus using previously published criteria. 10 For the purpose of this study, individuals were categorized as CU, having MCI, or having dementia. This study was approved by the Mayo Clinic and the Olmsted Medical Center institutional review boards. All participants provided written informed consent at the time of enrollment.
Imaging
Amyloid PET imaging was performed using Pittsburgh compound-B. Late uptake images were acquired from 40 to 60 minutes postinjection. A cortical composite meta region of interest was referenced to uptake in the cerebellar crus to create a standardized uptake value ratio (SUVR) as previously published. 11 Structural MRI was performed at 3T. Our N measure was a composite AD-characteristic cortical thickness measure averaging entorhinal, inferior temporal, middle temporal, and fusiform gyri thickness estimated using FreeSurfer 5.3. 12 Based on a recent analysis, amyloid PET SUVR values >1.42 (Centiloid 19) and cortical thickness values <2.67 mm were considered abnormal. 11 These cut points were used to form 4 groups:
A−N−, A+N−, A−N+, and A+N+.
Statistical Analysis
We investigated progression from CU to MCI or dementia, treating death prior to cognitive impairment as a competing event that precludes MCI or dementia. We defined baseline as a participant's first MCSA visit with both amyloid PET and MRI and limited our analysis to those who were CU and aged ≥70 years at this baseline and had some follow-up. To estimate rates of progression to MCI or dementia by biomarker group, we used Poisson regression including age, sex, education level, and A/N group as main effects. The absolute risk of observed cognitive impairment over time was computed using the competing risks approach described in Putter et al, 13 that is, accounting for some subjects never progressing to MCI/dementia because they die before doing so. We note that because MCSA visits occurred approximately 15 months apart and death could occur many years after the final clinical visit, only deaths that occurred within 15 months of a participant's last visit were counted as events.
Results
Of 763 CU participants, 26% were A−N−, 15% were A+N−, 30% were A−N+, and 28% were A+N+; demographic comparisons are shown in Table 1 . Men were more likely to be N+ (p = 0.002) and both A+ and N+ were associated with older age (p < 0.001). Over a median follow-up of 4 years, 159 21% individuals progressed to MCI (n = 152) or dementia (n = 7). About a quarter of our sample (24%) had one 15-month follow-up visit, 13% had 2, and 63% had ≥3. In our sample, progression rates expressed as events per 100 person-years (95% confidence interval [CI]) were 2.4 (1.8-3.2) at age 75 years and 6.5 (5.5-7.6) at age 85 years. Averaging over men and women and assuming some college education, progression rates (95% CIs) at age 75 years were 3.9 (2.7-5.7) among A+N+, 1.1 (0.7-1.9) among A−N−, 2.3 (1.4-3.7) among A+N−, and 2.3 (1.5-3.4) among A−N +. By age 85 years, the rates increased to 8.9 (6.8-11.5) among A+N+, 2.6 (1.5-4.3) among A−N−, 5.2 (3.3-8.1) among A+N−, and 5.1 (3.7-7.0) among A−N+. Treating the A−N− group as the reference, the relative rate (95% CI) for A+N+ was 3.5 (2.1-6.2), for A+N− it was 2.0 (1.1-3.9), and for A−N+ it was 2.0 (1.2-3.6). Within a biomarker group, rates were an estimated 20% higher in men (relative rate [RR] = 1.2, 95% CI = 0.9-1.7) and 30% higher in those with only a high school education (RR = 1.3, 95% CI = 1.0-1.9). The Figure 1 shows the estimated probability of cognitive impairment accounting for the competing risk of death for a 75-year-old and an 85-year-old with some college education averaged among men and women to emphasize risk differences by biomarker group. The data are plotted both with age and time in study on the abscissa. Table 2 shows the 5-and 10-year risks of progressing to MCI/dementia by age and sex for 2 levels of education. Based on the estimated risks, a CU 75-year-old A−N− woman with some college education has an estimated 6% chance of becoming cognitively impaired within 5 years. This increases to 19% assuming A+N+. Participants who were either A+N− or A−N+ had intermediate risks of progression. Table 2 also illustrates that risk clearly increases with age, is somewhat higher in men, and is somewhat lower for those with some college education.
Discussion
These results extend our work examining effects of amyloid positivity on cognition 14 to document the dual FIGURE 1: Probability of mild cognitive impairment or dementia over time accounting for the competing risk of death. Causespecific survival models were fit using age as the time scale (left column) and using years from imaging as the time scale (right column). Probabilities depend on age, and ages 75 and 85 years were chosen to illustrate this dependence. For simplification of presentation, estimates are shown averaged over sex and for an individual with some college education (ie, ≥13 years of education). A = amyloid; N = neuronal injury.
importance of amyloid positivity and neurodegeneration as substantial risk factors for cognitive impairment.
Having both normal amyloid and normal neurodegeneration was protective. In contrast, individuals with both abnormal amyloid and abnormal neurodegeneration had much higher rates of progression to MCI or dementia over an average of 4 years of follow-up. Interestingly, in the general community setting, the presence of either abnormal amyloid or neurodegeneration constituted a similar risk for progression. With the availability of imaging and/or CSF biomarker information in clinical practice, it is uncertain how to convey the data to patients. Our results provide easily interpretable estimates of the chance of becoming cognitively impaired in 5-and 10-year windows stratified by biomarker group. Furthermore, estimates are reported by 3 important risk factors: sex, education level, and age. Of these, risk varies to the greatest degree by age, but male sex and lower education are contributing factors that remain important in an era of biomarkers. 15 We have previously shown that these risk factors also influence MCSA participation, 16 and therefore it is important to account for them in regression analyses. Our biomarker findings should be interpreted in the context of previous reports, while recognizing that different definitions of amyloidosis and abnormal neurodegeneration using imaging-based versus CSF-based biomarkers make direct comparisons difficult. Using largely the same definition of A+ but an N+ based on abnormal hippocampal atrophy or abnormal FDG PET, an early report from the MCSA examining progression by 15 months found biomarker risk patterns that were quite similar to those reported here. 17 Conversely, 2 somewhat comparable studies offer little evidence that A−N+ is a risk factor for progression. Vos and colleagues used CSF biomarkers. 7 Their A+N+ group had the highest cumulative incidence Estimates are shown separately for men and women and by education level. a High school education is defined as ≤12 years of education; some college is defined as ≥13 years.
A = amyloid; F = female; M = male; N = neuronal injury.
of progression, followed by A+N−. However, the risk in their A−N+ group was comparable to that of the A−N− group. This disparate prognosis for SNAP individuals compared to our findings invites careful consideration of the processes underlying CSF-based or MRI-based definitions of N+. More recently, Burnham and colleagues reported that in the Australian Imaging, Biomarker, and Lifestyle study, those with A+N+, compared to A−N−, had a > 5-fold increased hazard of progression to MCI, those with A+N− had a > 2-fold increased hazard, and those with A−N+ had only a moderately elevated hazard (hazard ratio = 1.3). 6 With brain atrophy on MRI a wellestablished risk factor for cognitive impairment, and given our current findings, we think it likely that neurodegeneration in the absence of amyloidosis is an important risk factor for MCI. Furthermore, recent reports suggest amyloid and neurodegeneration are important complementary risk factors for dementia. 18, 19 There is likely risk associated with AD biomarker levels that are just below those deemed abnormal. Furthermore, the biomarker groups examined here do not address important neuropathological features such as cerebrovascular pathology, tau-based neurofibrillary tangles, TDP-43, and alpha synuclein. For a given individual, there are likely many factors contributing to cognitive function in aging. 20 Nonetheless, our absolute risk estimates may be useful to clinicians in counseling patients with respect to the role of AD biomarkers in aging or those planning clinical trials. Because these data were from a populationbased sample, they are less subject to biases that may be encountered in referral settings.
